Schöls L, Krüger R, Amoiridis G, Przuntek H, Epplen J T, Riess O
Department of Neurology, St Josef Hospital, Ruhr-University, Bochum, Germany.
J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):67-73. doi: 10.1136/jnnp.64.1.67.
Spinocerebellar ataxia type 6 (SCA6) is an autosomal dominant cerebellar ataxia (ADCA) of which the mutation causing the disease has recently been characterised as an expanded CAG trinucleotide repeat in the gene coding for the alpha1A-subunit of the voltage dependent calcium channel. The aim was to further characterise the SCA6 phenotype
The SCA6 mutation was investigated in 69 German families with ADCA and 61 patients with idiopathic sporadic cerebellar ataxia and the CAG repeat length of the expanded allele was correlated with the disease phenotype.
Expanded alleles were found in nine of 69 families as well as in four patients with sporadic disease. Disease onset ranged from 30 to 71 years of age and was significantly later than in other forms of ADCA. Age at onset correlated inversely with repeat length. The SCA6 phenotype comprises predominantly cerebellar signs in concordance with isolated cerebellar atrophy on MRI. Non-cerebellar systems were only mildly affected with external ophthalmoplegia, spasticity, peripheral neuropathy, and parkinsonism. Neither these clinical signs nor progression rate correlated with CAG repeat length.
This study provides the first detailed characterisation of the SCA6 phenotype. Clinical features apart from cerebellar signs were highly variable in patients with SCA6. By comparison with SCA1, SCA2, and SCA3 no clinical or electrophysiological finding was specific for SCA6. Therefore, the molecular defect cannot be predicted from clinical investigations. In Germany, SCA6 accounts for about 13% of families with ADCA. However, up to 30% of SCA6 kindreds may be misdiagnosed clinically as sporadic disease due to late manifestation in apparently healthy parents. Genetic testing is therefore recommended for the SCA6 mutation also in patients with putative sporadic ataxia.
6型脊髓小脑共济失调(SCA6)是一种常染色体显性遗传性小脑共济失调(ADCA),最近已明确其致病突变是电压依赖性钙通道α1A亚基编码基因中的CAG三核苷酸重复序列扩增。目的是进一步明确SCA6的表型特征。
对69个患有ADCA的德国家庭以及61例特发性散发性小脑共济失调患者进行SCA6突变检测,并将扩增等位基因的CAG重复长度与疾病表型进行关联分析。
在69个家庭中的9个以及4例散发性疾病患者中发现了扩增等位基因。发病年龄在30至71岁之间,明显晚于其他形式的ADCA。发病年龄与重复长度呈负相关。SCA6的表型主要包括小脑体征,与MRI上孤立的小脑萎缩一致。非小脑系统仅受到轻微影响,表现为外眼肌麻痹、痉挛、周围神经病变和帕金森综合征。这些临床体征和疾病进展速度均与CAG重复长度无关。
本研究首次对SCA6的表型进行了详细描述。SCA6患者除小脑体征外的临床特征高度可变。与SCA1、SCA2和SCA3相比,没有临床或电生理检查结果对SCA6具有特异性。因此,无法通过临床检查预测分子缺陷。在德国,SCA6约占ADCA家庭的13%。然而,由于明显健康的父母发病较晚,高达30%的SCA6家族可能在临床上被误诊为散发性疾病。因此,对于疑似散发性共济失调的患者,也建议进行SCA6突变的基因检测。